hämotherapie Ausgabe 8 2006

Aktuelles zur Diagnostik und Therapie der paroxysmalen nächtlichen Hämoglobinurie

1) *Parker C, Omine M, Richards S et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.*

2) *Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.*

3) *Hillmen P, Lewis SM, Bessler M et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.*

4) *Socie G, Mary JY, De Gramont A et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology [see comments]. Lancet 1996;348:573-7.*

5) *Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. Ser Heamatol 1972;5:3-23.*

6) *Luzzatto L. Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism. Curr Opin Genet Dev 2006;16:317-22.*

7) *Bessler M, Mason PJ, Hillmen P et al. Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1994;87:863-6.*

8) *Bessler M, Mason PJ, Hillmen P et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110-7.*

9) *Ware RE, Rosse WF, Howard TA. Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 1994;83:2418-22.*

10) *Mortazavi Y, Merk B, McIntosh J et al. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hotspot. Blood 2002.*

11) *Hugel B, Socie G, Vu T et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999;93:3451-6.*

12) *Vu T, Griscelli Bennaceur A, Gluckman E et al. Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets. Br J Haematol 1996;93:586-9.*

13) *Rother RP, Bell L, Hillmen P et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-62.*

14) *Schrezenmeier H, Hertenstein B, Wagner B et al. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins [published erratum appears in Exp Hematol 1995 Feb;23(2):181]. Exp Hematol 1995;23:81-7.*

15) *Schrezenmeier H, Hildebrand A, Rojewski M et al. Paroxysmal nocturnal haemoglobinuria: a replacement of haematopoietic tissue? Acta Haematol 2000;103:41-8.*

16) *Araten DJ, Nafa K, Pakdeesuwan K et al. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999;96:5209-14.*

17) Nebe T, Schubert, J. et al. Flow cytometric analysis of GPI-deficient cells for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). J Lab Med 2003;27:257-65.

18) Spath-Schwalbe E, Schrezenmeier H, Heimpel SH. [Paroxysmal nocturnal hemoglobinuria. Clinical experiences with 40 patients at one center over 25 years]
Paroxysmale nachtliche Hamoglobinurie. Klinische Erfahrungen bei 40 Patienten in einem Zentrum uber 25 Jahre. Dtsch Med Wochenschr 1995;120:1027-33.

19) Audebert HJ, Planck J, Eisenburg M et al. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol 2005;252:1379-86.

20) Frickhofen N, Heimpel H, Kaltwasser JP et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.

21) Saso R, Marsh J, Cevreska L et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;104:392-6.

22) Brecher ME, Taswell HF. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited. Transfusion 1989;29:681-5.

23) Knobloch K, Lichtenberg A, Schubert J et al. Paroxysmal nocturnal hemoglobinuria--pre- and perioperative rationale during cardiac surgery using extracorporeal circulation. Eur J Cardiothorac Surg 2004;26:1058-9.

24) Knobloch K, Zardo P, Gohrbandt B et al. Cardiac surgery in a patient with paroxysmal nocturnal hemoglobinuria. Haematologica 2002;87:ECR29.

25) Sloand EM, Maciejewski JP, Dunn D et al. Correction of the PNH defect by GPI-anchored protein transfer. Blood 1998;92:4439-45.

26) Sloand EM, Mainwaring L, Keyvanfar K et al. Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. Blood 2004;104:3782-8.

27) Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003;102:3587-91.

28) Moyo VM, Mukhina GL, Garrett ES et al. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004;126:133-8.

29) Hill A, Ridley SH, Esser D et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006;107:2131-7.

30) Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9.

31) Hill A, Hillmen P, Richards SJ et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65.

32) Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 2005;90:ECR40.

33) Hillmen, P., Muus, P., Dührsen, U., Risitano, A., Schubert, J., Young, N. S., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., Socie, G., Rollins, S. A., Rother, R. P., Bell, L., and Luzzatto, L. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood 108, 41a. 2006.